The stock of SeaSpine Holdings Corp (NASDAQ:SPNE) hit a new 52-week low and has $7.60 target or 14.00% below today’s $8.84 share price. The 6 months bearish chart indicates high risk for the $107.90M company. The 1-year low was reported on Nov, 10 by Barchart.com. If the $7.60 price target is reached, the company will be worth $15.11M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 11.69% or $1.17 during the last trading session, hitting $8.84. About 75,728 shares traded hands or 241.33% up from the average. SeaSpine Holdings Corp (NASDAQ:SPNE) has declined 29.01% since April 8, 2016 and is downtrending. It has underperformed by 34.66% the S&P500.
According to Zacks Investment Research, “SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California.”
More important recent SeaSpine Holdings Corp (NASDAQ:SPNE) news were published by: Streetinsider.com which released: “SeaSpine Holdings (SPNE) Reports FDA 510(k) Clearance for Mariner Posterior …” on November 07, 2016, also Globenewswire.com published article titled: “SeaSpine Holdings Corporation Announces Additions to Management Team”, Globenewswire.com published: “SeaSpine Launches Cambria(TM) NanoMetalene(R) Interbody Device” on October 16, 2015. More interesting news about SeaSpine Holdings Corp (NASDAQ:SPNE) was released by: Globenewswire.com and their article: “SeaSpine Launches Ventura(TM) NanoMetalene(R) Interbody Device” with publication date: August 10, 2015.
SPNE Company Profile
SeaSpine Holdings Corporation, incorporated on February 12, 2015, is a medical technology company. The Firm is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Firm operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment. The Firm has a portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic and cervical spine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.